Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

Novo Nordisk (NVO) announced Saturday that its pending acquisition of three Catalent (NYSE:CTLT) production sites is expected to close within days as its parent entity satisfied all regulatory ...

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give Novo Nordisk control of manufacturing facilities currently operated by ...

Novo Nordisk also reported the acquisition of three manufacturing sites from Novo Holdings A/S following the finalization of Novo Holdings' acquisition of Catalent, Inc. - a global contract ...

The Danish investment company Novo Nordisk A/S has received approval from the US Federal Trade Commission (FTC) to acquire the production assets of Catalent Inc., one of the world's largest ...

Moreover, free cash flow turned negative at minus DKK14.7 billion, largely due to heavy capital expenditures and the Catalent acquisition. Despite these challenges, Novo Nordisk remains well ...

NEW YORK, NY / ACCESS Newswire / March 8, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers ...

Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired ...

As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...

Novo Nordisk NVO shares have lost 21% in the past ... primarily driven by increased sales of Wegovy and Ozempic. The closing of the Catalent deal in December last year is also expected to help ...

Novo Nordisk also reinforced its leadership in the GLP-1 market, maintaining its dominant position with nearly two-thirds of all GLP-1 patients using its treatments. A key milestone for the company ...